InterHill MED Secures Tens of Millions in Pre-A Funding to Accelerate Development of Global-Leading Electrophysiology Technology Platform

VCBeat has learned at the earliest opportunity that recently, a leader in innovative electrophysiology technologyInterHill MED）Announced the completion of Pre-A round financing, led byShunwei Capital led the investment, with CASSTAR and Blue Ocean Capital participating as co-investors.. The proceeds from this round of financing will be primarily used forZhouling MedicalThe R&D of electrophysiology series products, clinical trials, new product portfolio planning, and the establishment of cutting-edge technology platforms are accelerating the market launch of the company’s innovative products, thereby benefiting patients in China and around the world.

(Product Logo)

Zhouling MedicalFounded in 2021, the founding team is among the world’s topR&D of Medical DevicesExpert, with decades of deep industry experience.

In terms of R&D strategy, Zhouling Medical is committed to innovativeElectrophysiology Devicesthe development of, has completed a multi-pipeline layout for neurophysiology equipment, cardiac electrophysiology equipment, and other major specialty medical devices such as those for oncology and cancer.

In terms of innovative R&D capabilities, Zhouling Medical centers its efforts on core R&D personnel who have returned from the United States and Germany. Through independent research and development as well as strategic collaborations with top-tier domestic and international research institutions, the company pursues joint innovation. Its electrophysiology equipment has received widespread acclaim from numerous leading clinical experts both in China and abroad for its smooth operation, precise positioning, realistic imaging, and outstanding performance, demonstrating significant clinical advantages and prominent technological leadership.

In terms of rapid product advancement, Zhouling Medical has finalized the design of its cardiac pulsed field ablation (PFA) device within less than a year since commencing R&D, and is poised to rapidly enter the clinical trial phase.

In addition, Zhouling Medical has established a research and development center in Shanghai, China, assembled a comprehensive R&D team, and built both its underlying technology platform and industrialization platform. The company has achieved full independent research and development of core technologies, including mapping architecture, electrical architecture, software architecture, complex algorithms, and scanning imaging systems. Looking ahead, the company will continue to focus on and meet the core clinical demands for safety, efficiency, and reliability in electrophysiology devices, actively promoting the regulatory approval and market launch of high-quality products in China and globally, thereby serving patients and healthcare providers worldwide.

The market for electrophysiology interventional devices in China is vast, with broad clinical applications anticipated in the future. The Chinese electrophysiology market is projected to reach nearly RMB 20 billion by 2024 for products related to electrophysiology procedures. Cardiac electrophysiology technology plays a crucial role in the diagnosis and treatment of arrhythmias and represents a highly dynamic field.

Zhouling MedicalR&DCardiac Pulsed Field Ablation (PFA) offers significant advantages in the treatment of atrial fibrillation. PFA is a novel ablation modality that utilizes pulsed electric fields as its energy source. By generating localized high-voltage gradients, it creates irreversible nanoscale pores in the cell membrane, leading to leakage of intracellular contents and thereby compromising membrane stability.

For the treatment of atrial fibrillation, current approaches primarily rely on radiofrequency ablation or cryoablation to restore and maintain sinus rhythm. Both methods have certain limitations, namely a lack of selectivity in destroying tissue within the ablation zone, which can easily cause injury to adjacent structures such as the esophagus and phrenic nerve. In contrast, pulsed field ablation (PFA) preserves the integrity of the tissue matrix within the ablation zone and can achieve effective tissue ablation without relying on close catheter-tissue contact.

InterHill MED is an R&D-driven innovative medical device company dedicated to providing high-quality medical devices to patients in China and worldwide for the treatment of neurological, cardiovascular, and other life-threatening critical conditions. Since commencing formal operations in 2021, the company has established a robust product pipeline spanning from preclinical to clinical stages through independent R&D and collaborative development, thereby creating a comprehensive electrophysiology equipment system solution. Its technical team, core members of which are R&D professionals returning from the United States and Germany, boasts decades of experience in medical device development and research, maintaining an absolute leading position in technological expertise within China. Guided by its vision of “Boundless Life, Leading Across the Five Continents,” InterHill MED focuses on the R&D, clinical translation, scaled manufacturing, and commercialization of first-in-class and best-in-class medical devices to address urgent unmet clinical needs.

CASSTAR is China’s first professional platform dedicated to venture capital investment and incubation in hard technology. As the originator of the “hard technology” concept and a pioneer in hard technology investment, CASSTAR is committed to building an integrated hard-tech entrepreneurial ecosystem that combines “research institutions + angel investment + entrepreneurial platforms + incubation services,” providing tech entrepreneurs with professional, in-depth, and comprehensive solutions for investment, incubation, and financing. Currently, CASSTAR manages several operational funds, including Xike Angel Fund I, Xike Angel Fund II, Xike Angel Fund III, Big Data Incubation Fund, Big Data Industry Fund, Xi’an CAS Growth Fund, Shaanxi Optoelectronic Integration Fund, Beijing Hard Tech Venture Capital Fund, and Beijing CASSTAR Hard Tech Fund II, with a cumulative total scale of RMB 5.3 billion.

Blue Ocean Capital focuses on growth-stage and M&A investments in innovative biopharmaceutical, medical device, and healthtech companies within the healthcare sector. Its core team possesses extensive international experience in scientific research, industry operations, and investment, managing multiple RMB and USD-denominated funds that have repeatedly received industry accolades. Recent investments by Blue Ocean Capital include several cutting-edge biopharmaceutical and medical device enterprises such as Zhouling Medical, Xige Life Sciences, Kokai Medical, Boan Biotech, Ribobio, and Junshengtai Biopharma. Since its inception, Blue Ocean Capital has adhered to a strategy of deep-value investing and value creation, driving positive transformations in portfolio companies through effective investment management while delivering long-term value to investors.